A
Ability Pharmaceuticals — Series A (estimated) · $1M
The Chinese drugmaker SciClone Pharmaceuticals became a shareholder in AbilityPharma with a $3M commitment: $1M invested immediately and $2M tied to development milestones. It was part of the €6.1M AbilityPharma raised in the second half of 2020, which also included a €2M Capital Cell crowdfunding, to develop ABTL0812 against pancreatic cancer.
Lead not disclosed
RoundSeries A (estimated)
Announced28 Dec 2020 · as AbilityPharma
CityCerdanyola del Vallès · reported Barcelona
SectorHealthtech & Bio · Biotech / Oncology
Source
A
The company
Investors 2
CCapital Cell
www.capitalcell.net
S
SciClone Pharmaceuticals